<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mes</journal-id><journal-title-group><journal-title xml:lang="ru">Экстремальная биомедицина</journal-title><trans-title-group xml:lang="en"><trans-title>Extreme Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3033-8964</issn><issn pub-type="epub">3033-8972</issn><publisher><publisher-name>Centre for Strategic Planning of the Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47183/mes.2023.058</article-id><article-id custom-type="elpub" pub-id-type="custom">mes-39</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Комбинация бактериофагов и антибиотиков как наиболее эффективный подход борьбы со Staphylococcus aureus</article-title><trans-title-group xml:lang="en"><trans-title>Combination of bacteriophages and antibiotics as the most effective therapy against Staphylococcus aureus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдраймова</surname><given-names>Н. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdraimova</surname><given-names>N. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нарина Казбековна Абдраймова</p><p>ул. Малая Пироговская, д. 1а, г. Москва, 119435</p></bio><bio xml:lang="en"><p>Narina K. Abdraimova</p><p>Malaya Pirogovskaya, 1a, Moscow, 119435</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шитиков</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shitikov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Городничев</surname><given-names>Р. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorodnichev</surname><given-names>R. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корниенко</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kornienko</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр физико-химической медицины имени Ю. М. Лопухина Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>10</month><year>2024</year></pub-date><volume>25</volume><issue>4</issue><fpage>39</fpage><lpage>47</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Абдраймова Н.К., Шитиков Е.А., Городничев Р.Б., Корниенко М.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Абдраймова Н.К., Шитиков Е.А., Городничев Р.Б., Корниенко М.А.</copyright-holder><copyright-holder xml:lang="en">Abdraimova N.K., Shitikov E.A., Gorodnichev R.B., Kornienko M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.extrememedicine.ru/jour/article/view/39">https://www.extrememedicine.ru/jour/article/view/39</self-uri><abstract><p>Staphylococcus aureus — бактериальный патоген, обладающий способностью к развитию антибиотикорезистентности и вызывающий ряд серьезных инфекций. Проблема терапии стафилококковых инфекций связана не только с устойчивостью штаммов к антибактериальным препаратам, но и со способностью бактерий формировать биопленки. Как альтернатива классической антибиотикотерапии рассматривается фаготерапия — использование вирулентных бактериофагов. Исследования, демонстрирующие действие бактериофагов против S. aureus, включают как отдельное использование фагов, так и их комбинацию с антибиотиками. Комбинированный подход представляется наиболее перспективным, так как позволяет значительно повысить эффективность терапии за счет синергического действия антибиотика и фага. В данном обзоре представлено обсуждение эффектов совместного применения двух агентов и методов их оценки. Обобщены результаты последних работ, посвященных комбинированному подходу против S. aureus в исследованиях in vitro и in vivo, а также в экспериментах по элиминации биопленки. Отдельное внимание уделено клиническим случаям лечения пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Staphylococcus aureus is a bacterial pathogen that is frequently associated with drug resistance and causes serious infectious diseases. The challenge in treating staphylococcal infections arises not only from the strains resistance to antibacterial drugs but also from the bacteria's capacity to form biofilms. As an alternative to traditional antibiotic therapy, phage therapy, employing virulent bacteriophages, is being explored. Research on bacteriophage's effectiveness against S. aureus encompasses both individual use and their combination with antibiotics. The combined approach appears most promising, enhancing therapeutic efficacy substantially through the synergistic action of both the antibiotic and the phage. This review discusses the effects of using both agents together and the methodologies for their evaluation. It summarizes the latest in vitro and in vivo research on the combined approach against S. aureus, including experiments focused on biofilm elimination. Special emphasis is placed on clinical case studies in treating patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>бактериофаги</kwd><kwd>Staphylococcus aureus</kwd><kwd>фаговая терапия</kwd><kwd>бактериофаговая терапия</kwd><kwd>комбинированная терапия</kwd><kwd>антибиотики</kwd><kwd>множе- ственная лекарственная устойчивость</kwd><kwd>биопленки</kwd><kwd>синергизм антибиотиков и бактериофагов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Bacteriophages</kwd><kwd>Staphylococcus aureus</kwd><kwd>phage therapy</kwd><kwd>bacteriophage therapy</kwd><kwd>combination therapy</kwd><kwd>antibiotics</kwd><kwd>multidrug resistance</kwd><kwd>biofilms</kwd><kwd>synergy between antibiotics and bacteriophages</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wagenlehner FME, Dittmar F. Re: global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Eur Urol. 2022; 82 (6): 658.</mixed-citation><mixed-citation xml:lang="en">Wagenlehner FME, Dittmar F. Re: global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Eur Urol. 2022; 82 (6): 658.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gherardi G. Staphylococcus aureus infection: pathogenesis and antimicrobial resistance. Int J Mol Sci. 2023; 24 (9): 81–82.</mixed-citation><mixed-citation xml:lang="en">Gherardi G. Staphylococcus aureus infection: pathogenesis and antimicrobial resistance. Int. J. Mol. Sci. 2023; 24 (9): 81–82.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fishovitz J, Hermoso JA, Chang M., Mobashery S. Penicillin- Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus. IUBMB Life. 2014; 66: 572–7.</mixed-citation><mixed-citation xml:lang="en">Fishovitz J, Hermoso JA, Chang M, Mobashery S. Penicillin- Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus. IUBMB Life. 2014; 66: 572–7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J. Biol. Med. 2017; 90: 269–81.</mixed-citation><mixed-citation xml:lang="en">McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017; 90: 269–81.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Burdett V. Tet(M)-promoted release of tetracycline from ribosomes is GTP dependent. J Bacteriol. 1996; 178: 3246–51.</mixed-citation><mixed-citation xml:lang="en">Burdett V. Tet(M)-promoted release of tetracycline from ribosomes is GTP dependent. J Bacteriol. 1996; 178: 3246–51.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Locke JB, Hilgers M, Shaw, KJ. Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700). Antimicrob Agents Chemother. 2009; 53: 5265–74.</mixed-citation><mixed-citation xml:lang="en">Locke JB, Hilgers M, Shaw, KJ. Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700). Antimicrob Agents Chemother. 2009; 53: 5265–74.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen SO, Lyon BR. Genetics of antimicrobial resistance in Staphylococcus aureus. Future Microbiol. 2009; 4: 565–82.</mixed-citation><mixed-citation xml:lang="en">Jensen SO, Lyon BR. Genetics of antimicrobial resistance in Staphylococcus aureus. Future Microbiol. 2009; 4: 565–82.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dashtbani-Roozbehani A, Brown MH. Efflux Pump Mediated Antimicrobial Resistance by Staphylococci in Health-Related Environments: Challenges and the Quest for Inhibition. Antibiot Basel Switz. 2021; 10: 1502.</mixed-citation><mixed-citation xml:lang="en">Dashtbani-Roozbehani A, Brown MH. Efflux Pump Mediated Antimicrobial Resistance by Staphylococci in Health-Related Environments: Challenges and the Quest for Inhibition. Antibiot Basel Switz. 2021; 10: 1502.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Idrees M, Sawant S, Karodia N, Rahman A. Staphylococcus aureus biofilm: morphology, genetics, pathogenesis and treatment strategies. Int J Environ Res Public Health. 2021; 18: 7602.</mixed-citation><mixed-citation xml:lang="en">Idrees M, Sawant S, Karodia N, Rahman A. Staphylococcus aureus biofilm: morphology, genetics, pathogenesis and treatment strategies. Int J Environ Res Public Health. 2021; 18: 7602.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Тикунова Н. В., Ворошилова Н. Н., Полыгач О. А., Морозова В. В., Тикунов А. Ю., Курильщиков А. М. и др. Генетическая характеристика и спектр антибактериальной активности бактериофагов, входящих в состав промышленных серий лекарственного препарата пиобактериофаг поливалентный очищенный. Эпидемиология и вакцинопрофилактика. 2016; 15 (2 (87)): 93–100.</mixed-citation><mixed-citation xml:lang="en">Tikunova NV, Voroshilova NN, Polygach OA, Morozova VV, Tikunov AY, Kurilshhikov AM, et al. Genetic characteristics and range of antibacterial activity of the bacteriophages, which are a part of manufactured serie of drugs — pyobacteriophage polyvalent purified. Epidemiology and Vaccinal Prevention. 2016; 15 (2 (87)): 93–100. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nikolich MP, Filippov AA. Bacteriophage therapy: developments and directions. Antibiotics. 2020; 9: 135.</mixed-citation><mixed-citation xml:lang="en">Nikolich MP, Filippov AA. Bacteriophage therapy: developments and directions. Antibiotics. 2020; 9: 135.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol. Ther. 2017; 8: 162–73.</mixed-citation><mixed-citation xml:lang="en">Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol. Ther. 2017; 8: 162–73.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kebriaei R, Lev KL, Stamper KC, Lehman SM, Morales S, Rybak MJ. Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrob Agents Chemother. 2021; 65 (1): e01863-20.</mixed-citation><mixed-citation xml:lang="en">Kebriaei R, Lev KL, Stamper KC, Lehman SM, Morales S, Rybak MJ. Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrob Agents Chemother. 2021; 65 (1): e01863-20.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Абдраймова Н. К., Корниенко М. А., Беспятых Д. А., Купцов Н. С., Городничев Р. Б., Шитиков Е. А. Комбинированное воздействие бактериофага vB_SauM-515A1 и антибиотиков на клинические изоляты Staphylococcus aureus. Вестник РГМУ. 2022; (5): 23–30.</mixed-citation><mixed-citation xml:lang="en">Abdraimova NK, Kornienko MA, Bespiatykh DA, Kuptsov NS, Gorodnichev RB, Shitikov EA. Combined effects of bacteriophage vB_SauM-515A1 and antibiotics on the Staphylococcus aureus clinical isolates. Bulletin of RSMU. 2022; (5): 23–30. Russian.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Simon K, Pier W, Krüttgen A, Horz HP. Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus. Antibiotics. 2021; 10 (7): 849.</mixed-citation><mixed-citation xml:lang="en">Simon K, Pier W, Krüttgen A, Horz HP. Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus. Antibiotics. 2021; 10 (7): 849.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dickey J, Perrot V. Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PloS One. 2019; 14 (1): e0209390.</mixed-citation><mixed-citation xml:lang="en">Dickey J, Perrot V. Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PloS One. 2019; 14 (1): e0209390.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zaytzeff-Jern H, Meleney FL. Studies in bacteriophage VI: The effect of sulfapyridine and sulfanilamide on staphylococci and E. Coli and their respective bacteriophages. J Lab Clin Med. 1941; 26: 1756–67.</mixed-citation><mixed-citation xml:lang="en">Zaytzeff-Jern H, Meleney FL. Studies in bacteriophage VI: The effect of sulfapyridine and sulfanilamide on staphylococci and E. Coli and their respective bacteriophages. J Lab Clin Med. 1941; 26: 1756–67.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Macneal WJ, Spence MJ, Blevins A. Cure of experimental staphylococcal meningitis. Exp Biol Med. 1942; 50: 176–9.</mixed-citation><mixed-citation xml:lang="en">Macneal WJ, Spence MJ, Blevins A. Cure of experimental staphylococcal meningitis. Exp Biol Med. 1942; 50: 176–9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Himmelweit F. Combined action of penicillin and phage on staphylococci. Lancet. 1945; 246: 104–5.</mixed-citation><mixed-citation xml:lang="en">Himmelweit F. Combined action of penicillin and phage on staphylococci. Lancet. 1945; 246: 104–5.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Diallo K, Dublanchet A. A century of clinical use of phages: a literature review. Antibiotics (Basel). 2023; 12 (4): 751.</mixed-citation><mixed-citation xml:lang="en">Diallo K, Dublanchet A. A century of clinical use of phages: a literature review. Antibiotics (Basel). 2023; 12 (4): 751.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Comeau AM, Tétart F, Trojet SN, Prère MF, Krisch HM. Phage- Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PloS One. 2007; 2 (8): e799.</mixed-citation><mixed-citation xml:lang="en">Comeau AM, Tétart F, Trojet SN, Prère MF, Krisch HM. Phage- Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PloS One. 2007; 2 (8): e799.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Vashisth M, Yashveer S, Anand T, Virmani N, Bera BC, Vaid RK. Antibiotics targeting bacterial protein synthesis reduce the lytic activity of bacteriophages. Virus Res. 2022; 321: 198909.</mixed-citation><mixed-citation xml:lang="en">Vashisth M, Yashveer S, Anand T, Virmani N, Bera BC, Vaid RK. Antibiotics targeting bacterial protein synthesis reduce the lytic activity of bacteriophages. Virus Res. 2022; 321: 198909.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Rahman M, Kim S, Kim SM, Seol SY, Kim J. Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. Biofouling. 2011; 27 (10): 1087–93.</mixed-citation><mixed-citation xml:lang="en">Rahman M, Kim S, Kim SM, Seol SY, Kim J. Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. Biofouling. 2011; 27 (10): 1087–93.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kumaran D, Taha M, Yi Q, et al. Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front Microbiol. 2018; 9: 127.</mixed-citation><mixed-citation xml:lang="en">Kumaran D, Taha M, Yi Q, et al. Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front Microbiol. 2018; 9: 127.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kirby AE. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS One. 2012; 7 (11): e51017.</mixed-citation><mixed-citation xml:lang="en">Kirby AE. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS One. 2012; 7 (11): e51017.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Tkhilaishvili T, Trampuz A. Adjunctive Use of Phage Sb-1 in Antibiotics Enhances Inhibitory Biofilm Growth Activity versus Rifampin-Resistant Staphylococcus aureus Strains. Antibiotics (Basel). 2020; 9 (11): 749.</mixed-citation><mixed-citation xml:lang="en">Wang L, Tkhilaishvili T, Trampuz A. Adjunctive Use of Phage Sb-1 in Antibiotics Enhances Inhibitory Biofilm Growth Activity versus Rifampin-Resistant Staphylococcus aureus Strains. Antibiotics (Basel). 2020; 9 (11): 749.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chhibber S, Kaur T, Sandeep Kaur. Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS One. 2013; 8 (2): e56022.</mixed-citation><mixed-citation xml:lang="en">Chhibber S, Kaur T, Sandeep Kaur. Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS One. 2013; 8 (2): e56022.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Prazak J, Iten M, Cameron DR, et al. Bacteriophages Improve Outcomes in Experimental Staphylococcus aureus Ventilator- associated Pneumonia. Am J Respir Crit Care Med. 2019; 200 (9): 1126–33.</mixed-citation><mixed-citation xml:lang="en">Prazak J, Iten M, Cameron DR, et al. Bacteriophages Improve Outcomes in Experimental Staphylococcus aureus Ventilator- associated Pneumonia. Am J Respir Crit Care Med. 2019; 200 (9): 1126–33.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Save J, Que YA, Entenza JM, Kolenda C, Laurent F, Resch G. Bacteriophages combined with subtherapeutic doses of flucloxacillin act synergistically against Staphylococcus aureus experimental infective endocarditis. J Am Heart Assoc. 2022; 11 (3): e023080.</mixed-citation><mixed-citation xml:lang="en">Save J, Que YA, Entenza JM, Kolenda C, Laurent F, Resch G. Bacteriophages combined with subtherapeutic doses of flucloxacillin act synergistically against Staphylococcus aureus experimental infective endocarditis. J Am Heart Assoc. 2022; 11 (3): e023080.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kornienko M, Kuptsov N, Gorodnichev R, et al. Contribution of Podoviridae and Myoviridae bacteriophages to the effectiveness of anti-staphylococcal therapeutic cocktails. Sci Rep. 2020; 10 (1): 18612.</mixed-citation><mixed-citation xml:lang="en">Kornienko M, Kuptsov N, Gorodnichev R, et al. Contribution of Podoviridae and Myoviridae bacteriophages to the effectiveness of anti-staphylococcal therapeutic cocktails. Sci Rep. 2020; 10 (1): 18612.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Hu T, Wei J, et al. Characterization of a Novel Bacteriophage Henu2 and Evaluation of the Synergistic Antibacterial Activity of Phage-Antibiotics. Antibiotics (Basel). 2021; 10 (2): 174.</mixed-citation><mixed-citation xml:lang="en">Li X, Hu T, Wei J, et al. Characterization of a Novel Bacteriophage Henu2 and Evaluation of the Synergistic Antibacterial Activity of Phage-Antibiotics. Antibiotics (Basel). 2021; 10 (2): 174.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kim M, Jo Y, Hwang YJ, et al. Phage-Antibiotic Synergy via Delayed Lysis. Appl Environ Microbiol. 2018; 84 (22): e02085-18.</mixed-citation><mixed-citation xml:lang="en">Kim M, Jo Y, Hwang YJ, et al. Phage-Antibiotic Synergy via Delayed Lysis. Appl Environ Microbiol. 2018; 84 (22): e02085-18.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kebriaei R, Lev K, Morrisette T, Stamper KC, Abdul-Mutakabbir JC, Lehman SM, et al. Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus. Antimicrob Agents Chemother. 2020; 64 (7): e00461-20.</mixed-citation><mixed-citation xml:lang="en">Kebriaei R, Lev K, Morrisette T, Stamper KC, Abdul-Mutakabbir JC, Lehman SM, et al. Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus. Antimicrob Agents Chemother. 2020; 64 (7): e00461-20.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Berryhill BA, Huseby DL, McCall IC, Hughes D, Levin BR. Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections. Proc Natl Acad Sci USA. 2021; 118 (10): e2008007118.</mixed-citation><mixed-citation xml:lang="en">Berryhill BA, Huseby DL, McCall IC, Hughes D, Levin BR. Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections. Proc Natl Acad Sci USA. 2021; 118 (10): e2008007118.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Loganathan A, Manohar P, Nachimuthu R. Phage-antibiotic combination: an effective method for eradication of Staphylococcus aureus. bioRxiv. Available from: https://www.biorxiv.org/content/10.1101/2023.03.27.534482v2.</mixed-citation><mixed-citation xml:lang="en">Loganathan A, Manohar P, Nachimuthu R. Phage-antibiotic combination: an effective method for eradication of Staphylococcus aureus. bioRxiv. Available from: https://www.biorxiv.org/content/10.1101/2023.03.27.534482v2.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Gilbert P, Maira-Litran T, McBain AJ, Rickard AH, Whyte FW. The physiology and collective recalcitrance of microbial biofilm communities. Adv Microb Physiol. 2002; 46: 202–56.</mixed-citation><mixed-citation xml:lang="en">Gilbert P, Maira-Litran T, McBain AJ, Rickard AH, Whyte FW. The physiology and collective recalcitrance of microbial biofilm communities. Adv Microb Physiol. 2002; 46: 202–56.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence. 2011; 2 (5): 445–59.</mixed-citation><mixed-citation xml:lang="en">Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence. 2011; 2 (5): 445–59.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs. 2005; 28 (11): 1062–8.</mixed-citation><mixed-citation xml:lang="en">Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs. 2005; 28 (11): 1062–8.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira WF, Silva PMS, Silva RCS, et al. Staphylococcus aureus and Staphylococcus epidermidis infections on implants. J Hosp Infect. 2018; 98 (2): 111–7.</mixed-citation><mixed-citation xml:lang="en">Oliveira WF, Silva PMS, Silva RCS, et al. Staphylococcus aureus and Staphylococcus epidermidis infections on implants. J Hosp Infect. 2018; 98 (2): 111–7.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Cho OH, Bae IG, Moon SM, Park SY, Kwak YG, Kim BN, et al. Therapeutic outcome of spinal implant infections caused by Staphylococcus aureus: A retrospective observational study. Medicine (Baltimore). 2018; 97 (40): e12629.</mixed-citation><mixed-citation xml:lang="en">Cho OH, Bae IG, Moon SM, Park SY, Kwak YG, Kim BN, et al. Therapeutic outcome of spinal implant infections caused by Staphylococcus aureus: A retrospective observational study. Medicine (Baltimore). 2018; 97 (40): e12629.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Kaur S, Harjai K, Chhibber S. Bacteriophage mediated killing of Staphylococcus aureus in vitro on orthopaedic K wires in presence of linezolid prevents implant colonization. PLoS One. 2014; 9 (3): e90411.</mixed-citation><mixed-citation xml:lang="en">Kaur S, Harjai K, Chhibber S. Bacteriophage mediated killing of Staphylococcus aureus in vitro on orthopaedic K wires in presence of linezolid prevents implant colonization. PLoS One. 2014; 9 (3): e90411.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Joo H, Wu SM, Soni I, Wang-Crocker C, Matern T, Beck JP, et al. Phage and Antibiotic Combinations Reduce Staphylococcus аureus in Static and Dynamic Biofilms Grown on an Implant Material. Viruses. 2023; 15 (2): 460.</mixed-citation><mixed-citation xml:lang="en">Joo H, Wu SM, Soni I, Wang-Crocker C, Matern T, Beck JP, et al. Phage and Antibiotic Combinations Reduce Staphylococcus aureus in Static and Dynamic Biofilms Grown on an Implant Material. Viruses. 2023; 15 (2): 460.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Taha M, Arnaud T, Lightly TJ, Peters D, Wang L, Chen W, et al. Combining bacteriophage and vancomycin is efficacious against MRSA biofilm-like aggregates formed in synovial fluid. Front Med (Lausanne). 2023; 10: 1134912.</mixed-citation><mixed-citation xml:lang="en">Taha M, Arnaud T, Lightly TJ, Peters D, Wang L, Chen W, et al. Combining bacteriophage and vancomycin is efficacious against MRSA biofilm-like aggregates formed in synovial fluid. Front Med (Lausanne). 2023; 10: 1134912.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Akturk E, Oliveira H, Santos SB, Costa S, Kuyumcu S, Melo LDR, et al. Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing Efficacy Against Mono and Dual-Species Biofilms. Antibiotics (Basel). 2019; 8 (3): 103.</mixed-citation><mixed-citation xml:lang="en">Akturk E, Oliveira H, Santos SB, Costa S, Kuyumcu S, Melo LDR, et al. Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing Efficacy Against Mono and Dual-Species Biofilms. Antibiotics (Basel). 2019; 8 (3): 103.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Doub JB, Ng VY, Lee M, Chi A, Lee A, Würstle S, et al. Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics (Basel). 2022; 11 (5): 616.</mixed-citation><mixed-citation xml:lang="en">Doub JB, Ng VY, Lee M, Chi A, Lee A, Würstle S, et al. Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics (Basel). 2022; 11 (5): 616.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M. Bacteriophage therapy in implant-related infections: an experimental study. J Bone Joint Surg Am. 2013; 95 (2): 117–25.</mixed-citation><mixed-citation xml:lang="en">Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M. Bacteriophage therapy in implant-related infections: an experimental study. J Bone Joint Surg Am. 2013; 95 (2): 117–25.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Gilbey T, Ho J, Cooley LA, Petrovic Fabijan A, Iredell JR. Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus. Med J Aust. 2019; 211 (3): 142-143.e1.</mixed-citation><mixed-citation xml:lang="en">Gilbey T, Ho J, Cooley LA, Petrovic Fabijan A, Iredell JR. Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus. Med J Aust. 2019; 211 (3): 142-143.e1.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Aslam S, Pretorius V, Lehman SM, Morales S, Schooley RT. Novel bacteriophage therapy for treatment of left ventricular assist device infection. J Heart Lung Transplant. 2019; 38 (4): 475–6.</mixed-citation><mixed-citation xml:lang="en">Aslam S, Pretorius V, Lehman SM, Morales S, Schooley RT. Novel bacteriophage therapy for treatment of left ventricular assist device infection. J Heart Lung Transplant. 2019; 38 (4): 475–6.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Ramirez-Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes MV, et al. Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy. Viruses. 2021; 13 (6): 1182.</mixed-citation><mixed-citation xml:lang="en">Ramirez-Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes MV, et al. Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy. Viruses. 2021; 13 (6): 1182.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
